MANNKIND Business Summary

MannKind Corporation (MNKD) is a commercial-stage biopharmaceutical company that generates revenue through a diversified mix of direct product sales, high-margin royalties, and manufacturing collaborations. The company’s primary business segments are Endocrine—centered on its proprietary Technosphere® dry-powder inhalation platform—and Orphan Lung/Cardiometabolic diseases. Key revenue drivers include Afrezza® (inhaled insulin), the V-Go® wearable delivery device, and FUROSCIX® (subcutaneous furosemide), the latter acquired via the 2025 merger with scPharmaceuticals. Additionally, MannKind earns significant royalty income and manufacturing fees from United Therapeutics for Tyvaso DPI®, a product utilizing MannKind’s inhalation technology for pulmonary arterial hypertension. Positioned as a specialized leader in non-invasive drug delivery, MannKind competes directly with global insulin giants Eli Lilly, Novo Nordisk, and Sanofi, as well as orphan disease players like United Therapeutics and Liquidia, distinguishing itself through its rapid-onset pulmonary delivery kinetics. Founded in 1991 by the late billionaire medical pioneer Alfred E. Mann, the company is currently led by CEO Michael Castagna, PharmD, a former Amgen and Bristol-Myers Squibb executive who has steered the firm toward sustained profitability and portfolio diversification. The executive team includes CFO Christopher Prentiss, who joined in 2024 from ADARx Pharmaceuticals, Chief Medical Officer Ajay Ahuja (appointed 2025), and CTO Joseph Kocinsky, who oversees the Danbury manufacturing facility. The company is governed by a board chaired by Dr. James Shannon, former Chief Medical Officer of GSK, and includes notable members such as former Northrop Grumman CEO Kent Kresa. MannKind maintains a strong institutional investor base, with significant positions held by BlackRock, The Vanguard Group, State Street, and specialized healthcare funds like Nitorum Capital and Rubric Capital Management.